Nicole Houston
Overview
Explore the profile of Nicole Houston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
348
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atkins S, Greer Y, Jenkins S, Gatti-Mays M, Houston N, Lee S, et al.
Oncologist
. 2023 Jun;
28(10):919-e972.
PMID: 37279797
Background: ONC201 is a small molecule that can cause nonapoptotic cell death through loss of mitochondrial function. Results from the phase I/II trials of ONC201 in patients with refractory solid...
2.
Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C, et al.
J Exp Clin Cancer Res
. 2023 Apr;
42(1):102.
PMID: 37101182
No abstract available.
3.
Cole C, Morelli M, Fantini M, Miettinen M, Fetsch P, Peer C, et al.
J Exp Clin Cancer Res
. 2023 Mar;
42(1):76.
PMID: 36991390
Background: NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by...
4.
Jenkins S, Zhang W, Steinberg S, Nousome D, Houston N, Wu X, et al.
Clin Cancer Res
. 2023 Jan;
29(8):1450-1459.
PMID: 36705597
Purpose: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention...
5.
Green D, Ning F, Duemler A, Myers T, Trewhitt K, Ekwede I, et al.
Clin Cancer Res
. 2023 Jan;
29(2):501.
PMID: 36647676
No abstract available.
6.
Green D, Ning F, Duemler A, Myers T, Trewhitt K, Ekwede I, et al.
Clin Cancer Res
. 2022 Sep;
29(2):349-363.
PMID: 36099324
Purpose: Ovarian cancer is the most lethal gynecologic cancer and intrinsically resistant to checkpoint immunotherapies. We sought to augment innate immunity, building on previous work with IFNs and monocytes. Patients...
7.
Zimmer A, Steinberg S, Smart D, Gilbert M, Armstrong T, Burton E, et al.
Future Oncol
. 2020 Apr;
16(14):899-909.
PMID: 32270710
Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in...
8.
Lampert E, Hays J, Kohn E, Annunziata C, Minasian L, Yu M, et al.
Oncotarget
. 2019 May;
10(30):2855-2868.
PMID: 31080557
To investigate maximum tolerated dose (MTD), activity and predictive biomarkers of olaparib with carboplatin in wild-type (wt) high grade serous ovarian carcinoma (HGSOC) patients. A 3+3 dose escalation study examined...
9.
Lee J, Cimino-Mathews A, Peer C, Zimmer A, Lipkowitz S, Annunziata C, et al.
J Clin Oncol
. 2017 May;
35(19):2193-2202.
PMID: 28471727
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular endothelial growth factor receptor inhibition may complement antitumor activity of...
10.
Lee J, Peer C, Yu M, Amable L, Gordon N, Annunziata C, et al.
Clin Cancer Res
. 2016 Sep;
23(6):1397-1406.
PMID: 27663600
Our preclinical studies showed that the PARP inhibitor, olaparib, prior to carboplatin attenuated carboplatin cytotoxicity. We evaluated sequence-specific pharmacokinetic and pharmacodynamic effects, safety, and activity of the combination. Eligible patients...